Reviewer's report

Title: Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

Version: 1 Date: 20 May 2013

Reviewer: Suzanne Dahlberg

Reviewer's report:

I have reviewed this paper and have found it to be well written. Below please find my comments for the authors:

Major Compulsory Revisions

1. The reported range in tumor size for this study is 0.8-4.8cm, but my understanding of T2aN0 disease per AJCC 7th edition is that these tumors should be >3cm in size. Can the authors please clarify this discrepancy?

2. It would seem that a sensitivity analysis of the CALGB 9633 analysis using the 4cm cutpoint would be valuable here, since that cutpoint is being used to define eligibility criteria for ongoing and future adjuvant trials.

3. With a median followup of 49 months, it would be helpful if the authors could discuss whether or not this is adequately long enough given how short it seems relative to the OS for this population, and the small sample size.

Minor Revisions

1. A reference for the statement that the proportion of early stage NSCLC has increased would be useful.

2. Please clarify the DFS definition - does this include recurrences in the opposite lung and second primaries? Death without recurrence?

3. Please clarify how many OS events there were in the results section.

4. Could the authors please provide a reference for the genomics and proteomic approaches that they allude to in the discussed as relevant for determining risk of recurrence? Are there validated approaches for this?

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:
I declare that I have no competing interests.